Merck Shares Jump After Dual Trial Successes Bolster Keytruda Outlook
Merck shares moved higher in pre-market trading after its KEYNOTE-C93 Phase 3 trial met the primary endpoint for progression-free survival in mismatch repair deficient advanced or recurrent endometrial cancer, and a partner-led Phase 3 study combining sacituzumab tirumotecan with pembrolizumab also met its primary endpoint in PD-L1 negative non-sma…